Bio­Th­eryX col­lects $92M in Se­ries E round; WuXi Bi­o­log­ics ups its stake in an emerg­ing ADC play­er

Bio­Th­eryX is con­tin­u­ing to rake in in­vestor cap­i­tal, net­ting a fresh $92 mil­lion Se­ries E round on Thurs­day.

The San Diego-based com­pa­ny not­ed it will fund at least two spe­cif­ic pro­grams in its an­nounce­ment: BTX-A51 and BTX-1188. The for­mer, Bio­Th­eryX’s lead can­di­date, is a mul­ti-ki­nase in­hibitor look­ing at p53 pro­tein mod­u­la­tion in acute myeloid leukemia, myelodys­plas­tic syn­drome and sol­id tu­mors. BTX-A51 is cur­rent­ly in a Phase I tri­al for r/r AML.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER